title: The functions and applications of RGD in tumor therapy and tissue engineering.
abstract: Arginine-Glycine-Aspartic (RGD), is the specific recognition site of integrins with theirs ligands, and regulates cell-cell and cell-extracellular matrix interactions. The RGD motif can be combined with integrins overexpressed on the tumor neovasculature and tumor cells with a certain affinity, becoming the new target for imaging agents, and drugs, and gene delivery for tumor treatment. Further, RGD as a biomimetic peptide can also promote cell adherence to the matrix, prevent cell apoptosis and accelerate new tissue regeneration. Functionalizing material surfaces with RGD can improve cell/biomaterial interactions, which facilitates the generation of tissue-engineered constructs. This paper reviews the main functions and advantages of RGD, describes the applications of RGD in imaging agents, drugs, gene delivery for tumor therapy, and highlights the role of RGD in promoting the development of tissue engineering (bone regeneration, cornea repair, artificial neovascularization) in recent years.
authors.affiliation: College of Material Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou 310036, China. waming@hznu.edu.cn.
authors.forename: Fen
authors.initials: F
authors.lastname: Wang
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Li
authors.forename: Yingqiang
authors.initials: Y
authors.lastname: Shen
authors.forename: Anming
authors.initials: A
authors.lastname: Wang
authors.forename: Shuling
authors.initials: S
authors.lastname: Wang
authors.forename: Tian
authors.initials: T
authors.lastname: Xie
mesh_terms: D000818:Animals; D040761:Biomimetic Materials / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D018014:Gene Transfer Techniques; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors / Q000378:metabolism; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D009842:Oligopeptides / Q000627:therapeutic use*; D023822:Tissue Engineering / Q000379:methods*
chemical_list: D016023:Integrins; D009363:Neoplasm Proteins; D009842:Oligopeptides; C047981:arginyl-glycyl-aspartic acid